We use cookies to understand how you use our site and to improve your experience. This includes personalizing content and advertising. To learn more, click here. By continuing to use our site, you accept our use of cookies, revised Privacy Policy and Terms of Service.
You are being directed to ZacksTrade, a division of LBMZ Securities and licensed broker-dealer. ZacksTrade and Zacks.com are separate companies. The web link between the two companies is not a solicitation or offer to invest in a particular security or type of security. ZacksTrade does not endorse or adopt any particular investment strategy, any analyst opinion/rating/report or any approach to evaluating individual securities.
If you wish to go to ZacksTrade, click OK. If you do not, click Cancel.
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil
Read MoreHide Full Article
Agios Pharmaceuticals, Inc. (AGIO - Free Report) reported a loss of $1.81 per share from continued operations for the fourth quarter of 2021, wider than the Zacks Consensus Estimate of a loss of $1.71 as well as the year-ago quarter’s loss of $1.22.
Following the sale of its oncology portfolio to France-based pharmaceutical company Servier, AGIO recorded zero revenues for the fourth quarter. The Zacks Consensus Estimate for the metric was $2.1 million. In the year-ago quarter, Agios recorded $44 million of total revenues.
Last week, the FDA approved its lead pipeline candidate mitapivat for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. The drug to be marketed by the trade name of Pyrukynd is the first disease-modifying therapy approved to treat this rare and debilitating blood disorder. A regulatory application for the drug for a similar indication is pending in the European Union and a decision is expected by this year-end.
Shares of Agios were down 2.5% in pre-market trading on Feb 24 following the above announcement. In fact, the stock has declined 47.9% in the trailing 12 months compared with the industry’s 19.2% decrease.
Image Source: Zacks Investment Research
Quarter in Detail
Research & development expenses increased 23.4% year over year to $73.3 million due to a rise in cost related to the planned initiation of late-stage studies of Pyrukynd for thalassemia and sickle cell disease (SCD), a blood disorder.
Selling, general and administrative expenses were up 21.7% year over year to $31.5 million, primarily due to launch preparations for Pyrukynd as well as expenses incurred to educate consumers about the PK deficiency disease
At the end of December 2021, cash, cash equivalents and marketable securities were $1.3 billion compared with $1.4 billion at the end of September 2021.
Pipeline Updates
Apart from PK deficiency, Agios is evaluating Pyrukynd for SCD and thalassemia indications.
AGIO initiated two phase III studies, namely ENERGIZE and ENERGIZE-T, to evaluate Pyrukynd for thalassemia in adults, with one segment being not regularly transfused while the other being regularly transfused. Agios plans to complete enrolment in both studies by 2022-end. Agios also plans to initiate two phase III studies that evaluate Pyrukynd in pediatric patients who are not regularly transfused and are regularly transfused, respectively, by mid-2022.
AGIO also initiated the phase II/III RISE UP study evaluating Pyrukynd for SCD. It plans to complete enrolling patients in the study by 2022-end.
Apart from Pyrukynd, Agios is evaluating AG-946, its next-generation pyruvate kinase-R activator. AGIO is currently evaluating the candidate in a phase I study for the treatment of hemolytic anemia.
Agios also intends to evaluate AG-946 for other indications. While a phase I study to evaluate the candidate for SCD is expected to begin in first-half 2022, a phase IIa study on the candidate for low- to intermediate-risk myelodysplastic syndrome (MDS) is planned to start by 2022-end.
Adaptimmune Therapeutics’ loss per share estimates for 2022 have narrowed from 99 cents to 91 cents in the past 30 days. Earnings of ADAP beat estimates in three of the last four quarters and missed the mark on a single occasion, the average surprise being 0.9%.
Arbutus Biopharma’s loss per share estimates for 2022 have narrowed from 63 cents to 61 cents in the past 30 days. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions. ABUS delivered a negative surprise of 3.6%, on average.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $13.35 to $14.33 in the past 30 days. The same for 2023 has risen from $14.12 to $15.31 in the past 30 days. Shares of VRTX have risen 6.3% in the past year.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, the average being 10%.
See More Zacks Research for These Tickers
Normally $25 each - click below to receive one report FREE:
Image: Bigstock
Agios (AGIO) Loss Wider Than Expected in Q4, Revenues Nil
Agios Pharmaceuticals, Inc. (AGIO - Free Report) reported a loss of $1.81 per share from continued operations for the fourth quarter of 2021, wider than the Zacks Consensus Estimate of a loss of $1.71 as well as the year-ago quarter’s loss of $1.22.
Following the sale of its oncology portfolio to France-based pharmaceutical company Servier, AGIO recorded zero revenues for the fourth quarter. The Zacks Consensus Estimate for the metric was $2.1 million. In the year-ago quarter, Agios recorded $44 million of total revenues.
Last week, the FDA approved its lead pipeline candidate mitapivat for hemolytic anemia in adults with pyruvate kinase (PK) deficiency. The drug to be marketed by the trade name of Pyrukynd is the first disease-modifying therapy approved to treat this rare and debilitating blood disorder. A regulatory application for the drug for a similar indication is pending in the European Union and a decision is expected by this year-end.
Shares of Agios were down 2.5% in pre-market trading on Feb 24 following the above announcement. In fact, the stock has declined 47.9% in the trailing 12 months compared with the industry’s 19.2% decrease.
Image Source: Zacks Investment Research
Quarter in Detail
Research & development expenses increased 23.4% year over year to $73.3 million due to a rise in cost related to the planned initiation of late-stage studies of Pyrukynd for thalassemia and sickle cell disease (SCD), a blood disorder.
Selling, general and administrative expenses were up 21.7% year over year to $31.5 million, primarily due to launch preparations for Pyrukynd as well as expenses incurred to educate consumers about the PK deficiency disease
At the end of December 2021, cash, cash equivalents and marketable securities were $1.3 billion compared with $1.4 billion at the end of September 2021.
Pipeline Updates
Apart from PK deficiency, Agios is evaluating Pyrukynd for SCD and thalassemia indications.
AGIO initiated two phase III studies, namely ENERGIZE and ENERGIZE-T, to evaluate Pyrukynd for thalassemia in adults, with one segment being not regularly transfused while the other being regularly transfused. Agios plans to complete enrolment in both studies by 2022-end. Agios also plans to initiate two phase III studies that evaluate Pyrukynd in pediatric patients who are not regularly transfused and are regularly transfused, respectively, by mid-2022.
AGIO also initiated the phase II/III RISE UP study evaluating Pyrukynd for SCD. It plans to complete enrolling patients in the study by 2022-end.
Apart from Pyrukynd, Agios is evaluating AG-946, its next-generation pyruvate kinase-R activator. AGIO is currently evaluating the candidate in a phase I study for the treatment of hemolytic anemia.
Agios also intends to evaluate AG-946 for other indications. While a phase I study to evaluate the candidate for SCD is expected to begin in first-half 2022, a phase IIa study on the candidate for low- to intermediate-risk myelodysplastic syndrome (MDS) is planned to start by 2022-end.
Agios Pharmaceuticals, Inc. Price
Agios Pharmaceuticals, Inc. price | Agios Pharmaceuticals, Inc. Quote
Zacks Rank & Stocks to Consider
Currently, Agios has a Zacks Rank #3 (Hold). Better-ranked stocks in the overall healthcare sector include Adaptimmune Therapeutics , Arbutus Biopharma (ABUS - Free Report) and Vertex Pharmaceuticals (VRTX - Free Report) , each carrying a Zacks Rank #2 (Buy) at present. You can see the complete list of today’s Zacks #1 Rank (Strong Buy) stocks here.
Adaptimmune Therapeutics’ loss per share estimates for 2022 have narrowed from 99 cents to 91 cents in the past 30 days. Earnings of ADAP beat estimates in three of the last four quarters and missed the mark on a single occasion, the average surprise being 0.9%.
Arbutus Biopharma’s loss per share estimates for 2022 have narrowed from 63 cents to 61 cents in the past 30 days. Earnings of ABUS beat estimates in one of the last four quarters, met the mark once and missed the same on the other two occasions. ABUS delivered a negative surprise of 3.6%, on average.
Vertex Pharmaceuticals’ earnings per share estimates for 2022 have increased from $13.35 to $14.33 in the past 30 days. The same for 2023 has risen from $14.12 to $15.31 in the past 30 days. Shares of VRTX have risen 6.3% in the past year.
Earnings of Vertex Pharmaceuticals beat estimates in each of the last four quarters, the average being 10%.